The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment.

Hossein PoustchiSara Majd JabbariShahin MeratAmir-Houshang SharifiAli Akbar ShayestehElahe ShayestehMohammad MinakariMohammad Reza FattahiMaryam MoiniFatemeh RoozbehFariborz Mansour-GhanaeiBehrooz AfsharMarjan MokhtareTaghi AmirianiMasoomeh SofianMohammad-Hossein SomiShahram AgahIradj MalekiMaryam LatifniaMojtaba Fattahi AbdizadehAhmad HormatiMasoud KhoshniaMasoudreza SohrabiZeinab MalekzadehDorsa MeratReza Malekzadeh

Published in: Journal of gastroenterology and hepatology (2020)

The combination of sofosbuvir and daclatasvir is an effective and safe treatment for patients infected with all genotypes of hepatitis C who have severe renal impairment, including patients on hemodialysis.

Keyphrases

end stage renal disease
hepatitis c virus
chronic kidney disease
peritoneal dialysis
ejection fraction
newly diagnosed
prognostic factors
early onset
combination therapy
patient reported outcomes
drug induced